| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 365.12% | JMP Securities | → $19 | Reiterates | Market Outperform → Market Outperform |
| 08/10/2023 | 46.88% | RBC Capital | → $6 | Initiates Coverage On | → Outperform |
| 08/08/2023 | 193.76% | Needham | $13 → $12 | Maintains | Buy |
| 06/21/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 05/19/2023 | 365.12% | JMP Securities | $16 → $19 | Maintains | Market Outperform |
| 05/16/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 03/31/2023 | 291.68% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 03/31/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/03/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/01/2023 | 291.68% | JMP Securities | $14 → $16 | Maintains | Market Perform |
| 11/11/2022 | 218.24% | Needham | $12 → $13 | Maintains | Buy |
| 08/12/2022 | 291.68% | Truist Securities | $27 → $16 | Maintains | Buy |
| 08/09/2022 | 242.72% | JMP Securities | $19 → $14 | Maintains | Market Outperform |
| 08/09/2022 | 193.76% | Needham | $20 → $12 | Maintains | Buy |
| 05/14/2021 | 609.91% | Needham | $31 → $29 | Maintains | Buy |
| 02/17/2021 | 658.87% | Needham | → $31 | Initiates Coverage On | → Buy |
| 02/02/2021 | 756.79% | Truist Securities | $20 → $35 | Maintains | Buy |
| 09/29/2020 | 438.56% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 09/21/2020 | 389.6% | Truist Securities | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 144.8% | HC Wainwright & Co. | $14 → $10 | Maintains | Buy |
| 05/12/2020 | 193.76% | B. Riley Securities | $10 → $12 | Maintains | Buy |
| 03/18/2020 | 144.8% | B. Riley Securities | $15 → $10 | Maintains | Buy |
| 12/18/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy |
What is the target price for Cormedix (CRMD)?
The latest price target for Cormedix (NASDAQ: CRMD) was reported by JMP Securities on November 15, 2023. The analyst firm set a price target for $19.00 expecting CRMD to rise to within 12 months (a possible 365.12% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cormedix (CRMD)?
The latest analyst rating for Cormedix (NASDAQ: CRMD) was provided by JMP Securities, and Cormedix reiterated their market outperform rating.
When is the next analyst rating going to be posted or updated for Cormedix (CRMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Cormedix (CRMD) correct?
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a reiterated with a price target of $0.00 to $19.00. The current price Cormedix (CRMD) is trading at is $4.09, which is within the analyst's predicted range.